SCHEMBL5280341

SCHEMBL5280341

Cc1c(C(N)=O)c2ccccc2[nH]c1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
DAO P14920 1/20 0.56
DDO Q99489 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 1/20 0.50
NR4A2 P43354 1/20 0.47
MAPT P10636 2/20 0.47
IDE P14735 1/20 0.47
MPI P34949 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
LMNA P02545 3/20 0.47
TNKS O95271 1/20 0.47
CYP1A2 P05177 1/20 0.47
PARP1 P09874 1/20 0.47
GPR3 P46089 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8930304 0.87 DAO (0.60) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL4895906 0.85 KDM4E (0.72) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL3624515 0.81 NR4A2 (0.65) KDM4EALDH1A1KMT2AMEN1HSD17B10
SCHEMBL10175975 0.81 NR4A2 (0.69) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL26351505 0.81 EGFR (0.61) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL5171220 0.78 KDM4E (0.50) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL1228041 0.78 KDM4E (0.62) KDM4ETDP1ALDH1A1KMT2AMEN1
SCHEMBL1621884 0.78 KDM4E (0.68) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL26349973 0.77 KDM4E (0.71) KDM4EDAODDOTDP1ALDH1A1
SCHEMBL31146399 0.77 KDM4E (0.56) KDM4EDAODDOTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363925-B8 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2007-04-25 EP disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 EP disclosed
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 US disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 US disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 EP disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 KDM4E 1204/4885DAO 4429/4885DDO 4797/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 KDM4E 1204/4885DAO 4429/4885DDO 4797/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 KDM4E 1358/4885DAO 4211/4885DDO 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.